MX2017009253A - Anticuerpos antiglicoproteina y usos de los mismos. - Google Patents
Anticuerpos antiglicoproteina y usos de los mismos.Info
- Publication number
- MX2017009253A MX2017009253A MX2017009253A MX2017009253A MX2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A MX 2017009253 A MX2017009253 A MX 2017009253A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- methods
- produced
- glycoprotein
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describe una nueva clase de anticuerpo con especificidad por glicoproteínas. Se muestra que los anticuerpos se unen de forma específica a proteínas manosiladas, tales como proteínas producidas por hongos. Se proveen ensayos que utilizan dichos anticuerpos antiglicoproteína para monitorear la presencia de glicoproteínas en una muestra. Dichos métodos se pueden utilizar para monitorear métodos de producción y/o purificación de los polipéptidos deseados, los que se pueden usar para modificar parámetros de procesos para modificar (por ejemplo, reducir u aumentar) la cantidad de polipéptido glicosilado producido y/o presente en el producto purificado. También se proveen métodos para utilizar los anticuerpos sujeto para detectar el nivel de expresión y secreción de un polipéptido y métodos para utilizar los anticuerpos sujeto para purificar una muestra o eliminar las glicoproteínas de una muestra. En ejemplos de modalidades, el polipéptido deseado puede ser una proteína de múltiples subunidades, tal como un anticuerpo, que se puede producir en una levadura, tal como Pichia pastoris.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562104407P | 2015-01-16 | 2015-01-16 | |
PCT/US2016/013701 WO2016115521A1 (en) | 2015-01-16 | 2016-01-15 | Anti-glycoprotein antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017009253A true MX2017009253A (es) | 2017-10-12 |
Family
ID=56406494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017009253A MX2017009253A (es) | 2015-01-16 | 2016-01-15 | Anticuerpos antiglicoproteina y usos de los mismos. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180142038A1 (es) |
EP (1) | EP3244738A4 (es) |
JP (1) | JP2018511300A (es) |
KR (1) | KR20170116050A (es) |
CA (1) | CA2974033A1 (es) |
MX (1) | MX2017009253A (es) |
SG (2) | SG10201906597TA (es) |
WO (1) | WO2016115521A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3034795A1 (en) * | 2018-02-27 | 2019-08-27 | Pfizer Inc. | Antibody purification |
AU2019369421A1 (en) * | 2018-10-31 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
CN113164566A (zh) * | 2018-11-07 | 2021-07-23 | 第一三共株式会社 | Klk5抑制性肽 |
CN113980092B (zh) * | 2021-12-09 | 2024-05-14 | 上海药明生物技术有限公司 | 一种蛋白质亲和纯化方法 |
CN114130377A (zh) * | 2021-12-14 | 2022-03-04 | 无锡创谱生物科技有限公司 | 一种亲和层析填料、其制备方法及用途 |
CN114199875B (zh) * | 2022-02-18 | 2022-05-20 | 之江实验室 | 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
CA2623197A1 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
CN103992405B (zh) * | 2008-03-26 | 2016-08-17 | 宜康公司 | 抗-vegf抗体 |
US8399625B1 (en) * | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
CN105392883A (zh) * | 2013-03-15 | 2016-03-09 | 格里科比亚有限公司 | 聚唾液酸、血型抗原以及糖蛋白表达 |
-
2016
- 2016-01-15 US US15/544,163 patent/US20180142038A1/en not_active Abandoned
- 2016-01-15 CA CA2974033A patent/CA2974033A1/en not_active Abandoned
- 2016-01-15 WO PCT/US2016/013701 patent/WO2016115521A1/en active Application Filing
- 2016-01-15 JP JP2017537373A patent/JP2018511300A/ja active Pending
- 2016-01-15 SG SG10201906597TA patent/SG10201906597TA/en unknown
- 2016-01-15 SG SG11201705748SA patent/SG11201705748SA/en unknown
- 2016-01-15 MX MX2017009253A patent/MX2017009253A/es unknown
- 2016-01-15 EP EP16738007.0A patent/EP3244738A4/en not_active Withdrawn
- 2016-01-15 KR KR1020177022748A patent/KR20170116050A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
EP3244738A1 (en) | 2017-11-22 |
WO2016115521A1 (en) | 2016-07-21 |
JP2018511300A (ja) | 2018-04-26 |
KR20170116050A (ko) | 2017-10-18 |
US20180142038A1 (en) | 2018-05-24 |
SG11201705748SA (en) | 2017-08-30 |
SG10201906597TA (en) | 2019-08-27 |
EP3244738A4 (en) | 2018-12-05 |
CA2974033A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017009253A (es) | Anticuerpos antiglicoproteina y usos de los mismos. | |
MX353144B (es) | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. | |
SG10201909806SA (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
RU2018108836A (ru) | ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
EA201300048A1 (ru) | Система экспрессии гетерологичных и гомологичных целлюлаз | |
EA201070987A1 (ru) | Очищенные гибридные белки иммуноглобулина и способы их очищения | |
SG10201902850TA (en) | Human-derived anti-dipeptide repeats (dprs) antibody | |
EA201590994A1 (ru) | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина | |
WO2015013388A3 (en) | Anti-galectin-1 monoclonal antibodies and fragments thereof | |
SG10201807572PA (en) | Robust antibody purification | |
MX2018012550A (es) | Composiciones y metodos para la deteccion de proteinas de celulas huesped. | |
RU2015129656A (ru) | Гуманизированное моноклональное антитело, специфичное к синдекану-1 | |
MX2020000288A (es) | Cromatografia. | |
EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
TR201907379T4 (tr) | Yeni anti-insan PAI-1 antikoru. | |
NZ631116A (en) | Process for preparing apolipoprotein a-i (apo a-i) | |
EA028913B9 (ru) | Получение антител высокой чистоты в pichia pastoris | |
EA201892231A1 (ru) | Способ очистки белка | |
EA201690271A1 (ru) | Конструкции для экспрессии и способы экспрессии полипептидов в клетках эукариот | |
ZA202203400B (en) | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis | |
EP2647609A3 (de) | Glutaminreiche Peptide als Luftporenbildner in Baustoffmassen | |
WO2018069640A3 (fr) | Procédé de diagnostic/détermination de l'efficacité de traitement de la dépression | |
ZA202002083B (en) | Antibody purification | |
MX2016002188A (es) | Composición farmacéutica de proteínas híbridas recombinantes capaces de generar anticuerpos neutralizantes en contra del veneno de alacranes. | |
EP2708555A3 (en) | Polyclonal antibodies to cloned fungal polypeptide targets |